The FDA on June 23 announced a 5-year strategy for improving and extending the lives of people with rare neurodegenerative diseases by advancing development of safe and effective medical products and facilitating access to novel treatments.
The plan, which will serve as a blueprint for how the agency will move forward in tackling challenges in drug development, was developed in accordance with the Accelerating Access to Critical Therapies for ALS Act that President Joe Biden signed into law in December 2021, the FDA said in a press release…
